maplirpacept + carfilzomib + dexamethasone

This is a combination regimen of **maplirpacept** (PF-07901801), **carfilzomib**, and **dexamethasone** under investigation for the treatment of relapsed or refractory multiple myeloma. - **Maplirpacept** is a recombinant fusion protein designed to inhibit CD47, a “don’t eat me” signal upregulated on tumor cells, thereby promoting phagocytosis by macrophages. - **Carfilzomib** is a second-generation, irreversible proteasome inhibitor (PI) that induces apoptosis in cancer cells by blocking protein degradation. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and antineoplastic effects, commonly used as part of combination therapy in multiple myeloma. This regimen is currently being evaluated in phase 1 clinical trials to determine safety, tolerability, and optimal dosing. The primary clinical context is relapsed/refractory multiple myeloma[1][3][5][7].

Other names

maplirpacept + carfilzomib + dexamethasonecarfilzomib + dexamethasone + maplirpacept